Research
European cardiovascular magnetic resonance (EuroCMR) registry – multi national results from 57 centers in 15 countries
1 Department of Cardiology and Angiology, Contilia Heart and Vascular Center, Essen, Germany
2 Comprehensive Cardiology of Stamford and Greenwich, Stamford, CT, USA
3 C.N.R./Regione Toscana “G. Monasterio Foundation”, Pisa, Italy
4 Cardiac MR Centre, University Hospital (CHUV), Lausanne, Switzerland
5 Department of Cardiology, VU Medical Centre, Amsterdam, The Netherlands
6 Department of Cardiology, Hospital Agatharied, Hausham, Germany
7 Department of Cardiology, Klinikum Ludwigsburg, Germany
8 Department of Cardiology, University of Heidelberg, Heidelberg, Germany
9 Barts and The London NIHR Biomedical Research Unit, The London Chest Hospital, London, UK
10 King’s College London BHF Centre of Excellence, Division of Imaging Sciences, NIHR Biomedical Research Centre at Guy’s and St.Thomas’ NHS Trust Foundation, The Rayne Institute, St. Thomas’ Hospital, London, UK
11 CMR Unit, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK
12 Department of Cardiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376, Stuttgart, Germany
13 Department of Internal Medicine, Krankenhaus Benrath, Düsseldorf, Germany
14 Department of Internal Medicine and Cardiology, Donauklinikum Tulln, Austria
15 Institut für Herzinfarktforschung, Ludwigshafen, Germany
Journal of Cardiovascular Magnetic Resonance 2013, 15:9 doi:10.1186/1532-429X-15-9
Published: 18 January 2013Abstract
Background
The EuroCMR registry sought to evaluate indications, image quality, safety and impact on patient management of clinical routine CMR in a multi-national European setting. Furthermore, interim analysis of the specific protocols should underscore the prognostic potential of CMR.
Methods
Multi-center registry with consecutive enrolment of patients in 57 centers in 15 countries. More than 27000 consecutive patients were enrolled.
Results
The most important indications were risk stratification in suspected CAD/Ischemia (34.2%), workup of myocarditis/cardiomyopathies (32.2%), as well as assessment of viability (14.6%). Image quality was diagnostic in more than 98% of cases. Severe complications occurred in 0.026%, always associated with stress testing. No patient died during or due to CMR. In 61.8% CMR findings impacted on patient management. Importantly, in nearly 8.7% the final diagnosis based on CMR was different to the diagnosis before CMR, leading to a complete change in management. Interim analysis of suspected CAD and risk stratification in HCM specific protocols revealed a low rate of adverse events for suspected CAD patients with normal stress CMR (1.0% per year), and for HCM patients without LGE (2.7% per year).
Conclusion
The most important indications in Europe are risk stratification in suspected CAD/Ischemia, work-up of myocarditis and cardiomyopathies, as well as assessment of viability. CMR imaging is a safe procedure, has diagnostic image quality in more than 98% of cases, and its results have strong impact on patient management. Interim analyses of the specific protocols underscore the prognostic value of clinical routine CMR in CAD and HCM.
The EuroCMR registry sought to evaluate indications, image quality, safety and impact on patient management of clinical routine CMR in a multi-national European setting in a large number of cases (n > 27000). Based on our data CMR is frequently performed in European daily clinical routine. The most important indications in Europe are risk stratification in suspected CAD/Ischemia, work-up of myocarditis and cardiomyopathies, as well as assessment of viability. CMR imaging is a safe procedure, has diagnostic image quality in more than 98% of cases, and its results have strong impact on patient management. Interim analyses of the specific protocols underscore the prognostic value of clinical routine CMR in CAD and HCM.
